495P Safety and efficacy of nab-sirolimus (HB1901) + endocrine therapy in HR+/HER2- advanced breast cancer after standard therapy failure: A multicenter, open-label, phase 2 study

Fei Ma, Hongnan Mo, Jie Cui et al.|Annals of Oncology|2025

Cited by 0